Cabozantinib Plus Nivolumab/Ipilimumab Meets PFS End Point in Untreated Advanced RCC
July 11th 2022The addition of cabozantinib to nivolumab and ipilimumab generated a significant improvement in progression-free survival vs nivolumab/ipilimumab alone as a first-line treatment for patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma, meeting the primary end point of the phase 3 COSMIC-313 trial.
Read More
Enoblituzumab Trial Ended Early Due to Safety Concerns in Head and Neck Squamous Cell Carcinoma
July 11th 2022The phase 2 CP-MGA271-06 trial closed early following an internal review of safety data of enoblituzumab plus retifanlimab or tebotelimab as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
Read More
FDA Issues Warning for Increased Risk of Death, Serious AEs with Duvelisib in CLL/SLL
July 1st 2022The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer
June 29th 2022Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.
Read More
Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma
June 28th 2022The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.
Read More
CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer
June 27th 2022The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.
Read More
Iopofosine I-131 Under Further Investigation in CLOVER WaM Trial in Waldenström Macroglobulinemia
June 23rd 2022Sikander Ailawadhi, MD, discusses early efficacy observed with iopofosine I-131, the rationale of investigating the agent in the CLOVER WaM trial in patients with Waldenström macroglobulinemia, and how the radiotherapeutic could affect the treatment paradigm.
Read More
CHMP Recommends Melphalan Flufenamide for Triple-Class Refractory Multiple Myeloma
June 23rd 2022The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.
Read More
Nemtabrutinib Generates Responses, Displays Manageable Safety in CLL/SLL
June 20th 2022Nemtabrutinib, a potent, non-covalent BTK inhibitor, continued to demonstrate antitumor activity with an acceptable safety profile in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
Cilta-cel Produces Durable Responses in Relapsed/Refractory Multiple Myeloma
June 20th 2022A single infusion of the CAR T-cell therapy ciltacabtagene autoleucel produced deep and durable responses in patients with relapsed/refractory multiple myeloma with a manageable toxicity profile, according to long-term follow-up data of the phase 1b/2 CARTITUDE-1 trial.
Read More
Repotrectinib Receives Breakthrough Therapy Designations in China for ROS1+ NSCLC
June 17th 2022The China National Medical Products Administration’s Center for Drug Evaluation granted 2 breakthrough therapy designations to repotrectinib for the treatment of patients with ROS1-positive metastatic non–small cell lung cancer.
Read More
Using NGS to Detect NRG1 Fusions Could Guide Treatment in NSCLC and Other Solid Tumors
June 14th 2022Next-generation panel sequencing and a unique algorithm demonstrated the advantage of detecting NRG1 fusions and providing structure information of partners, which could ultimately guide more precise therapeutic options, according to data from a study done in Chinese patients with solid tumors.
Read More
Ropeginterferon Alfa-2b Demonstrates Long-Term QOL Improvements in Polycythemia Vera
June 13th 2022Treatment with ropeginterferon alfa-2b-njft induced low symptom burden and low phlebotomy requirement compared with best available treatment in patients with polycythemia vera, according to long-term data from the phase 3 PROUD-PV and CONTINUATION-PV trials.
Read More
CAR T-Cell Therapy ARI0002H Elicits Encouraging Responses in Relapsed/Refractory Multiple Myeloma
June 11th 2022ARI0002H, a BCMA-directed CAR T-cell therapy, achieved promising response rates in patients with relapsed/refractory multiple myeloma, according to findings from a phase 1/2 trial.
Read More